TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Freeline To Present New Data On Its Gaucher And Parkinson S Disease Programs At The American Society Of Gene And Cell Therapy (ASGCT) 27Th Annual Meet menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS for Multiple Sclerosis. The Report Shows Compound to be Safe and Well Tolerated Toronto,.
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual.
Substantial reduction in lyso-Gb1 substrate levels, an established biomarker of clinical response, observed in first patient treated with FLT201 Increases of several hundredfold over baseline in.